NO20073765L - Forbindelser for behandling av flaviviridae - Google Patents

Forbindelser for behandling av flaviviridae

Info

Publication number
NO20073765L
NO20073765L NO20073765A NO20073765A NO20073765L NO 20073765 L NO20073765 L NO 20073765L NO 20073765 A NO20073765 A NO 20073765A NO 20073765 A NO20073765 A NO 20073765A NO 20073765 L NO20073765 L NO 20073765L
Authority
NO
Norway
Prior art keywords
flaviviridae
treatment
compounds
prevention
formula
Prior art date
Application number
NO20073765A
Other languages
English (en)
Inventor
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20073765L publication Critical patent/NO20073765L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sammendrag Utgreiet er ikke-immunundertrykkende syklofilinbindende syklosporiner, for eksempel med formel (I), (Ia) eller (II) som definert her, som har nyttige egenskaper i forhindringen eller behandlingen av flaviviridaeinfeksjoner og flaviviridaeinduserte lidelser.
NO20073765A 2004-12-23 2007-07-19 Forbindelser for behandling av flaviviridae NO20073765L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63867604P 2004-12-23 2004-12-23
PCT/US2005/046058 WO2006071618A1 (en) 2004-12-23 2005-12-20 Compounds for flaviviridae treatment

Publications (1)

Publication Number Publication Date
NO20073765L true NO20073765L (no) 2007-09-19

Family

ID=36218613

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073765A NO20073765L (no) 2004-12-23 2007-07-19 Forbindelser for behandling av flaviviridae

Country Status (17)

Country Link
US (1) US20090214464A1 (no)
EP (1) EP1830870A1 (no)
JP (1) JP2008525458A (no)
KR (1) KR20070089954A (no)
CN (1) CN101084005A (no)
AU (1) AU2005322241B2 (no)
BR (1) BRPI0519355A2 (no)
CA (1) CA2587586A1 (no)
IL (1) IL183780A0 (no)
MA (1) MA29097B1 (no)
MX (1) MX2007007721A (no)
NO (1) NO20073765L (no)
NZ (1) NZ555142A (no)
RU (1) RU2007128098A (no)
TN (1) TNSN07240A1 (no)
WO (1) WO2006071618A1 (no)
ZA (1) ZA200703907B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
WO2007041632A2 (en) 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI111730B (fi) * 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
CA2426381A1 (en) * 2000-10-19 2002-04-25 Fujisawa Pharmaceutical Co., Ltd. Cell damage inhibitor
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
ATE490778T1 (de) * 2004-10-01 2010-12-15 Debiopharm Sa Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
WO2006071619A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
AU2005322241B2 (en) 2010-02-18
JP2008525458A (ja) 2008-07-17
MX2007007721A (es) 2007-08-14
KR20070089954A (ko) 2007-09-04
ZA200703907B (en) 2009-08-26
WO2006071618A1 (en) 2006-07-06
US20090214464A1 (en) 2009-08-27
MA29097B1 (fr) 2007-12-03
AU2005322241A1 (en) 2006-07-06
NZ555142A (en) 2010-03-26
CA2587586A1 (en) 2006-07-06
CN101084005A (zh) 2007-12-05
IL183780A0 (en) 2007-09-20
EP1830870A1 (en) 2007-09-12
TNSN07240A1 (en) 2008-11-21
RU2007128098A (ru) 2009-01-27
BRPI0519355A2 (pt) 2009-01-20

Similar Documents

Publication Publication Date Title
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
TNSN07240A1 (en) Compounds for flaviviridae treatment
NO20073764L (no) Sammensetninger for behandling av HCV
EA200700488A1 (ru) S-ТРИАЗОЛИЛ-α-МЕРКАПТОАЦЕТАНИЛИДЫ КАК ИНГИБИТОРЫ ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20091247L (no) terapeutiske pyrazolyl tienopyridiner
NO20080879L (no) HCV-NS3-proteaseinhibitorer
EA201000329A1 (ru) Циклические депсипептиды
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20072235L (no) HCV-hemmende bicykliske pyrimidiner
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20073849L (no) Indolderivater for behandling av virale infeksjoner
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20076515L (no) Hydantoinforbindelser
NO20083694L (no) Bruk av rylener som markorer for vaesker
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20081844L (no) Terapeutiske forbindelser
NO20081628L (no) Benzodiazepiner som HCV-inhibitorer
NO20082496L (no) Pyrazinderivater
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20064584L (no) Tetrahydropyridoindolderivater
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application